Harvard medical

George Q. Daley, MD, PhD, Harvard Medical School’s newly appointed dean, led dozens of international colleagues in developing ethical guidelines for stem cell research. On March 9, 2009, President Barack H. Obama issued Executive Order 13505: Removing Barriers to Responsible Scientific Research involving Human Stem Cells, stating that the Secretary of Health and Human Services, through the Director of the National Institute of Health (NIH), may support and conduct responsible, scientifically worthy human stem cell research, including human embryonic stem cell (hESC) research, to the extent permitted by law. Internal NIH policies and procedures, consistent with Executive Order 13505 and these Guidelines, govern the conduct of intramural NIH stem cell research.

A prominent stem cell researcher has been named the new dean of Harvard Medical School, the university announced August 9th

George Q. Daley, MD, PhD, who led dozens of international colleagues to unite around ethical guidelines for stem cell research, isHarvard Medical taking on a new challenge—unifying the powerful hospitals that train Harvard’s medical students.

Daley will assume the position effective Jan. 1, 2017, succeeding Jeffrey Flier, MD, who stepped down July 31st. Barbara McNeil, MD, the founding head of the Department of Health Care Policy at Harvard Medical School, is filling the position in the interim.

The internationally recognized leader in stem cell science and cancer biology and a longtime member of the Harvard Medical School (HMS) faculty whose work includes the fields of basic science and clinical medicine, Daley was the driving force behind creating international guidelines around first, human embryonic stem cell research, and then the clinical application of stem cells, according to Nancy Witty, CEO of the International Society for Stem Cell Research (ISSCR).

Daley, who cofounded the organization, counseled two dozen scientists through the sensitive ethical discussions involved in establishing stem cell research guidelines, utilized additional input from 60 groups around the world to construct the guidelines which were first published by the National Institute of Health in 2009.

“That’s a very difficult task,” Witty said. “It takes a tremendous amount of diplomacy.” Harvard Medical

Daley is working to adapt insights in stem cell research to improved therapies for genetic and malignant diseases. Important research contributions from his laboratory at Harvard-affiliated Boston Children’s Hospital include the development of customized stem cells to treat genetic immune deficiency in a mouse model (in collaboration with Rudolf Jaenisch, a Professor of Biology at MIT); the differentiation of germ cells from embryonic stem cells (cited as a “Top Ten Breakthrough” by Science magazine in 2003), and the generation of disease-specific pluripotent stem cells by direct reprogramming of human fibroblasts (cited in the “Breakthrough of the Year” issue of Science magazine in 2008).

As a graduate student working with Nobel laureate Dr. David Baltimore, Daley demonstrated that the BCR/ABL oncogene induces chronic myeloid leukemia (CML) in a mouse model, which validated BCR/ABL as a target for drug blockade and encouraged the development of imatinib (GleevecTM; Novartis), a revolutionary magic-bullet chemotherapy that induces remissions in virtually every CML patient. Dr. Daley’s recent studies have clarified mechanisms of Gleevec resistance and informed novel combination chemotherapeutic regimens.

Daley has spent his entire career in Cambridge and Boston, earning a medical degree from Harvard and a PhD in biology from MIT. As Dean of Harvard Med School, Daley’s achievements in stem cell research is expected to shine a distinguished light on the stem cell industry.

Although the position of dean of Harvard Med may be one of the most prominent roles in medicine, the position is not as powerful it might seem: Harvard Med does not directly oversee any hospitals. Instead it relies on 15 affiliated hospitals and clinical sites, which have historically operated as separate, competitive bailiwicks, to train its students and postdoctoral fellows, and support its researchers. Only 151 of the nearly 12,000 people who call themselves Harvard Medical faculty actually work directly for Harvard in its 10 basic science departments.

Daley sees his new position as a congregator who “builds bridges among the institutions” —heavyweight research institutions such as Brigham and Women’s, Massachusetts General, and Boston Children’s hospitals. Persuasiveness, rather than power, is all that Daley says is needed to achieve an alliance.

Daley’s predecessor, Flier, says he spent a full 30 percent to 40 percent of his time as dean trying to build relationships with and coordinate Harvard’s affiliated hospitals and clinics, a challenge Daley says he’s up to. He has a head start in building those relationships through the many positions he has held around Boston’s biomedical community, including chief resident at Mass. General

“My vision is one of increasing connectivity across the community,” Daley says.

Currently a professor of biological chemistry and molecular pharmacology at Harvard Medical School and director of the stem cell transplantation program at Boston Children’s and Dana-Farber Cancer Institute, Daley sees areas of common interest, such as immuno-oncology, which harnesses the body’s own immune system against cancer cells, where the hospitals can work more closely together.

Described by colleagues as a natural leader, Daley recently led an effort to coordinate big-name scientists across several institutions on a collaborative grant to compare two types of stem cells—just one example of how he earned a reputation; he knows how to get different groups talking together in a constructive way.

He also says he wants Harvard Medical’s faculty, students, and staff to reflect the global community the school intends to serve, and that he promotes diversity in hiring for his 30-person lab.

Daley has a keen interest in sickle-cell anemia, which affects people of African descent, including African Americans, and he believes the federal government should invest in a moonshot effort to cure the disease.

Daley plans to continue teaching molecular medicine at Harvard Med after assuming his position as dean. He also plans to spend one day per week in his lab researching blood stem cells.

“It’s important for a dean to remain relevant by continuing to publish papers,” Daley says. “Plus, I just love science.”

Among his priorities is raising money. Despite its worldwide reputation, and its relative influence when it comes to landing federal grants, Harvard Med has seen annual deficits of between $31 million and $45 million for three consecutive years. Suggestions are being made for Harvard to rename its medical school in return for a billion-dollar donation. Daley only says that the idea would be worth considering down the road.

With opportunities for federal grants in decline, Daley says he sees an opportunity to bring in money from corporate partnerships.

For the stem cell research and medical community, Daley’s appointment as dean of Harvard Med is a fitting step toward validating regenerative medicine’s place as an authoritative leader in the future of medicine—one that’s been a long time coming.

Learn more about Dr. Daley here.

###

Alfredo Hoyos, M.D.

ISSCA Hoyos

Alfredo Hoyos, M.D., Global Stem Cells Group’s chief scientific officer (CSO), is a renowned  board-certified plastic surgeon from Bogotá, Colombia. Dr. Hoyos earned his medical degree at El Rosario University in Bogotá and performed his residency in plastic surgery at the Rosario – Saint Joseph Hospital, also in Bogotá.

The inventor of High Definition Liposculpture (HDL), Dynamic Definition Lipoplasty (4D), and other advanced body contouring techniques, Dr. Hoyos has been an innovator since early in his career, embracing the potential of stem cells early on. He is well known for his surgical skills, and recognizing new opportunities to advance the efficacy of health care treatments. One of the most promising breakthroughs toward that end is the acceleration of stem cell discoveries over the past 20 years.

Dr. Hoyos recognized the potential of these remarkable, undifferentiated cells, capable of  self-reinvention when called upon to take on the functions of other cells in the body when needed, giving rise to a new field of vision for the future of surgical and aesthetic protocols, and the future of medicine altogether. Dr. Hoyos adapts the healing  and restorative capabilities of stem cells  to the aesthetic procedures he performs—including fat grafting and fat transfer—and  has successfully performed assisted stem cell fat transfer procedures for patients looking to restore volume in the facial area that is lost in the natural aging process.

Dr. Hoyos continues to identify new opportunities in innovative medical technology that can improve the quality of patients’ lives.  After adopting and mastering  Vaser ultrasonic liposuction technology, also known as liposelection (an alternative to traditional liposuction) he later developed the Vaser Hi Definition Lipoplasty (VHD) procedure.

Dr. Hoyos founded Stem Lab, a biotechnology company based in Bogotá, to further the development of stromal stem cells derived from adipose tissue. He continues to develop and refine these techniques, while exploring new applications for HD and other emerging technologies  in the field of aesthetic  surgery.

He is an accomplished sculptor, painter, medical book illustrator and author. of several books focusing on high definition body sculpting and advanced lipoplasty techniques. Dr. Hoyos is certified by the Colombian Society of Plastic Surgery, (SCCP) and the  International Confederation of Plastic Reconstructive and Aesthetic Surgery (IPRAS).

total solution

MIAMI, Aug. 23, 2016 – Global Stem Cells Group and its subsidiary Adimarket announce a collaborative agreement with South Korean biomedical and lab equipment manufacturer N-Biotek to offer the Total Solution highly manipulated stem cell culture expansion lab, complete with equipment, training, facilities, stem cell processing center, clean rooms, project plan and more- a total turnkey lab solution for emerging stem cell businesses and industry professionals.

The announcement marks a new chapter in GSCG’s ongoing expansion, and commitment to bring stem cell therapies to

total solution

Physicians at work in Total Solution turnkey stem cell lab

patients worldwide. By joining with N-Biotek to bring this exceptional, ready-to-go stem cell culture expansion lab to scientists and institutions throughout North and South America, GSCG is facilitating research and development in the critical need areas of highly manipulated stem cell protocols and cryopreservation of cell colonies.

Until now, Admarket has been GSCG’s online marketplace for quality regenerative medicine equipment and supplies for physicians and health care professionals, offering basic tools and products to facilitate in-office stem cell procedures. However, through N-Biotek, Adimarket now offers the Total Solution labs and all the accoutrements. From planning to building the facility, to training and consultation, Total Solution users are equipped in every way possible to walk in and begin using their fully-equipped biotechnology lab in short order.

total solution

Total Solutions clean room and stem cell lab equipment

The collaboration with N-Biotek means GSCG and Adimarket can create a stem cell processing center for researchers who require more advanced lab environments to conduct complex research and develop processes and procedures for the fast-growing stem cell market.

The Stem Cell Total Solution is a comprehensive business solution that provides the entire stem cell processing system-from business planning to business procedures, a state-of-the-art cellular processing facility with bio safety clean rooms for stem cell processing, quality control rooms, core technology, cutting-edge equipment, installation, training-everything needed to launch a stem cell business or a enhance a medical research practice in a short period of time.

N-Biotek has been providing its Stem Cell Total Solution labs and consulting services, as well as stem cell processing technology management services, to universities, research centers, physicians and biotechnology enterprises in South Korea, China, Japan and Vietnam for years.

total solutionHighly manipulated stem cells are critical to biotechnology researchers in order to advance both fundamental knowledge of the undifferentiated cells that have the remarkable potential to develop into many different cell types in the body during early life and growth, and to find ways to use them to treat medical and cosmetic conditions non-invasively. Additionally, in many tissues, stem cells serve as a sort of internal repair system, dividing essentially without limit to replenish damaged and dead cells for as long as the person or animal they inhabit is alive.

When a stem cell divides, each new cell has the potential to remain a stem cell or become another type of cell with a more specialized function, such as a muscle cell, a red blood cell, or a brain cell, and this allows researchers to manipulate these extraordinary reconstructionist micro-organisms to differentiate into other cell types that can be used to treat disease and injuries affecting parts of the body from which they did not originate. For instance, a stem cell harvested from body fat can be manipulated to take on the functions of a pancreatic cell, a heart cell or a retina cell. Researchers see unlimited potential in their ability to heal wounds, cure diseases, and even prevent birth defects.

total solution“Non-destructive manipulation of stem cells in a precise environment is key to facilitating discoveries within the biology and medical research communities,” says Benito Novas, CEO of Global Stem Cells Group. “Our collaboration with N-Biotek to deliver the Total Solution for highly manipulated stem cell culture expansion labs to emerging stem cell scientists is the next phase in GSCG’s mission to fulfill our promise of making stem cell-based therapies available to patients everywhere.

“Stem cell manipulation resulting in cells that possess the characteristics necessary for successful differentiation, transplantation, and engraftment is critical to discovering new methods for treating illness and impairments,” Novas says.

Global Stem Cells Group and N-Biotek provide Total Solution users with everything they need to culture, expand and cryopreserve stem cells right away. Each system comes with manufacture patents and full certification. All products and total solutionequipment is made to comply with, or exceed standards required for CE Certification.

N-Biotek is the only company that builds the entire stem cell processing system for clients ready to begin a stem cell business, or establish a lab facility to enhance their medical or research practice.

To learn more about the N-Biotek Stem Cell Total Solution, visit the Global Stem Cells Group website at  or the AdiMarket website, email bnovas@stemcellsgroup.com, or call 305-560-5337.

About Global Stem Cells Group:
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

About Adimarket:
Adimarket, Inc., a subsidiary of Global Stem Cells Group, is a cost-competitive online marketplace for quality regenerative medicine equipment and supplies for physicians and health care professionals. Adimarket was founded to provide physicians and other health care professionals the tools they need to practice regenerative medicine in a medical office setting.

Motivated by a firm belief in the positive impact the practice of stem cell medicine can have when dispensed in a doctor’s office, Adimarket provides physicians with the tools they need to provide patients with cutting edge treatments. Adimarket’s experienced customer service representatives provide valuable guidance and advice regarding products relevant to individual practices.

About N-Biotek:
Since 1982, N-Biotek has been the leading manufacturer of biomedical and lab equipment worldwide. The Stem Cell Total Solution lab is a culmination of years of dedication to establish compact and customized products in developing the Handy Lab-a personal lab for medical, scientific and university professionals. N-Biotek is known for its high quality, uniquely designed biomedical products and equipment and competitive pricing. Over the years, the company’s products have earned an array of patents, and all meet international standards including CE, ETL, ISO and GMP. N-Biotek also offers real-time monitoring through IT technology.

Since 2010, N-Biotek has expanded significantly, starting new businesses including a stem cell processing system and biological clean room, GMP consulting, validation services and health care services for foreign consumers in order to maintain its lead in the life science field.

To view this press release live online, please click here

###

Stem cell training Madrid

 Global Stem Cells Group has announced a stem cell training course in Madrid, Spain, to be held Dec. 6 – 7, 2016, in collaboration with Javier Garcia Alonso, MD and Clinica Castellana Norte.

stem cell training Madrid

Physicians at a recent stem cell training course

MIAMI, Aug. 16, 2016—Global Stem Cells Group and Stem Cell Training, Inc. will host a stem cell training course in Madrid, Dec. 6-7, 2016, in collaboration with Javier Garcia Alonso, MD of Clinica Castellana Norte in Madrid. Garcia Alonso is a specialist in plastic, reconstructive and aesthetic surgery.

The stem cell training course, available to qualified physicians, will focus on stem cell protocols in cosmetic, anti-aging, and aesthetic procedures.

The Adipose and Bone Marrow Stem Cell Training Course was developed for physicians and high-level practitioners to learn the process through a two-day, intensive, hands-on training program to arm participating physicians with clinical protocols and state-of-the-art techniques for isolating and re-integrating adipose- and bone marrow-derived stem cells. When used in aesthetic medicine therapies, patients walk away with more natural-appearing augmentation and enjoy a faster recovery period with little to no downtime.

Garcia Alonso will host and participate in training qualified physicians in stem cell harvesting, isolating and re-integration stem cell training course in Barcelonatechniques and protocols, during which stem cells are harvested from the patient’s own body and redistributed to areas of the body receiving augmentation.

Stem cell therapy is a promising treatment for facial rejuvenation and soft tissue augmentation because there are no incisional scars or complications associated with foreign materials. Demand for stem cell procedures s high worldwide—these effective procedures that do not involve going under the knife are driving the growth of stem cell protocols in the cosmetic industry, as more patients request new technologies that are less invasive than ever before.

Breast augmentatistem cell training course in Barcelonaon, abdominoplasty, facelifts and liposuction continue to feature in the top most requested procedures for many clinics, surgeons say an increasing number of patients are seeking a more natural look with a quicker recovery time, according to Benito Novas, CEO of Global Stem Cells Group. In fact, non-surgical cosmetic procedures have grown exponentially over the past five years, and the trend is expected to continue to rise.

Surgeons are also seeing more diverClinica Castellana Norte.sity when it comes to the type of procedures requested, including buttock enhancements, hair transplantation and anti-aging procedures on hands.

“Patients are demanding procedures that are quick, easy, and provide a fast recovery with minimal downtime,” Novas says. “Stem cells provide the ability to rejuvenate and heal, making them a natural treatment for cosmetic and anti-aging applications.”

The stem cell training course will be offered through Global Stem Cells Group affiliate Stem Cell Training, Inc.

To learn more, visit the Global Stem Cells Group website, or the Stem Cell Training website, email bnovas(at)regenestem(dot)com, or call +1 305 560 5337.

About Global Stem Cell Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

About Stem Cell Training, Inc.:

Stem Cell Training, Inc. is a multi-disciplinary company offering coursework and training in 35 cities worldwide. The coursework offered focuses on minimally invasive techniques for harvesting stem cells from adipose tissue, bone marrow and platelet-rich plasma. By equipping physicians with these techniques, the goal is to enable them to return to their practices, better able to apply these techniques in patient treatments.

About Clinica Castellana Norte:

Clinica Castellana Norte in Madrid of
fers a comprehensive range of aesthetic and reconstructive procedures, from dietary advice to state-of-the-art stem cell therapies for cosmetic procedures. Clinica Castellana Norte operates under the highest quality standards, not only in medical and aesthetic treatments offered, but throughout the administrative process, ensuring privacy. Clinica Director Javier Garcia Alonso, M.D., is a member of the Spanish Society of Plastic Reconstructive and Aesthetic Surgery (SECPRE), and a member of the International Society of Plastic, Reconstructive and Aesthetic Surgery (IPRAS).

To view this press release live online, click here

###

Buenos Airies stem cell symposium

 

Global Stem Cells Group will honor Joseph Purita, MD at its 3rd Annual International Symposium on Stem Cells and Regenerative Medicine, to be held in Buenos Aires Sept. 28, 2016. Purita, an active contributor to the Miami-based biotech company, has been a key participant in GSCG’s growth since it launched in 2013.

Joseph Purita MD

Joseph Purita, MD

MIAMI, Aug. 16, 2016—Global Stem Cells Group plans to honor Joseph Purita, MD, during its 3rd Annual International Symposium on Stem Cells and Regenerative Medicine, to be held in Buenos Aires, Argentina Sept. 28, 2016. The symposium will be hosted in collaboration with Julio Ferreira, MD, President of the South American Academy Cosmetic Surgery, an event expected to attract a record number of physicians, researchers and regenerative medicine experts from around the world.

Julio Ferreira advisory board, Global Stem Cells Group

Julio Ferreira, MD

Purita, a renown orthopedic and arthroscopic surgeon heads GSCG’s Scientific Advisory Board. A pioneer in the use of Stem Cell and PRP therapy for orthopedic conditions, Purita has practiced with the Boca Raton Orthopaedic Group in Boca Raton, Florida since 1981. In 2012, Purita gained international attention when he treated New York Yankees pitcher Bartolo Colon’s ligament damage with stem cells, restoring the athlete’s injured shoulder and career. Purita has since treated an array of professional athletes with career-threatening injuries.

The GSCG Symposium offers an opportunity for many of the world’s most respected authorities on stem cell and regenerative medicine to join Purita and other industry leaders to showcase advancements in research and therapies on a global level.

Duncan Ross, PhD

Duncan Ross, PhD

An interdisciplinary team of stem cell experts will provide a full day of high-level scientific lectures geared to medical professionals. Pioneers and luminaries in stem cell medicine will serve as featured speakers, led by keynote speakers Purita and Duncan Ross, PhD Ross, a GSCG Advisory Board faculty member, is a molecular biologist, immunologist and researcher, and the founder of Kimera Labs.

According to Benito Novas, Global Stem Cells Group CEO, the world-class event will showcase the historic advances in stem cell medicine achieved since the first symposium was held just two years ago in 2014.

“We’ve come so far since 2014, and this year’s symposium will highlight the strides Global Stem Cells Group has made in these two years,” Novas says. “And it is only fitting that we take the opportunity to acknowledge Dr. Purita’s contributions to our growth.

“This year, we will showcase how far stem cell therapies have come, and provide some of the most influential leaders like Dr. Purita, who understand the potential of these therapies and have dedicated their careers to making them a reality.”

Since 2014, Global Stem Cells Group has joined forces with some of the most prestigious regenerative medicine practitioners in South America as it focuses on growing its services throughout the global community. Stem cell therapies continue to revolutionize the anti-aging aesthetics industry while offering new hope for sufferers of serious chronic debilitating diseases.

To learn more about the 3rd Annual International Symposium on Stem Cells and Regenerative Medicine, visit the Global Stem Cells Group website, email bnovas(at)regenestem(dot)com, or call 305-560-5337.

About Global Stem Cells Group:

stem cell training course in BarcelonaGlobal Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

About Joseph Purita, MD

Joseph Purita, MD, a pioneer in the use of Stem Cell and PRP therapy for orthopedic conditions, graduated from Georgetown University Medical School and served his surgical internship at the University of Florida Medical Center. Following completion of a residency in orthopedic surgery at University of Miami-Jackson Memorial Hospital, where he served as chief administrative resident, Dr. Purita joined the Boca Raton Orthopaedic Group in 1981.

Purita is a Fellow, American Academy of Orthopedic Surgeons; Fellow, American College of Surgeons; member, American Medical Association; member, Southern Medical Association; member, Palm Beach Medical Society; member, Broward County Medical Society; member, Palm Beach Orthopedic Society, and member, Florida Medical Association. His certifications include the American Board of Orthopedic Surgery; American College of Orthopaedic Surgery; American Board of Pain Management, and the American Board of Regenerative Medicine.

Purita is an instructor and proctor of surgeons in the use of lasers in arthroscopic and orthopedic surgery at a variety of area hospitals, and heads GSCG’s Scientific Advisory Board.

To view this press release live online, click here

###

Julio Ferreira, M.D.

Julio Ferreira advisory board, Global Stem Cells Group

Julio Ferreira, M.D.
Global Stem Cells Group Advisory Board member

Julio Ferreira, M.D., is an internationally recognized and respected cosmetic surgeon and professor of medicine and aesthetic surgery at the Institute of Biomedical Sciences, University of Sao Paulo, Brazil;

As director of Clinica Ferreira in Argentina, Dr. Ferreira is dedicated to the combination of art and science in aesthetic medicine.

Dr. Ferreira serves as president of the South American Academy of Cosmetic Surgery and expert examiner at the International Board of Cosmetic Surgery. He also serves on the International Editorial Advisory Board of the American Journal of Cosmetic Surgery; former President of the International Academy of Cosmetic Surgery 2005/2007; a member and examiner, International Board of Cosmetic Surgery; Corresponding Fellow of the American Academy of Cosmetic Surgery; Honorary Member of the Spanish Society of Cosmetic Medicine and Surgery; Honorary Member of the Eurorusa Confederation of Societies of Aesthetic Plastic Surgery; Honorary Member of the Bulgarian Society of Cosmetic Surgery; Honorary Member of the Chilean Society of Cosmetic Surgery and Lipoplasty; Honorary Member of the Italian Society of Aesthetic Surgery, and Honorary Member of the French Society of Aesthetic Surgery.

 

Duncan Ross, Ph.D.

Duncan Ross, PhD

Duncan Ross, Ph.D.
Global Stem Cells Group Advisory Board member

Duncan Ross, Ph.D., is a graduate of the University of Miami Immunology and Biochemistry departments where he specialized in stem cell transplantation and protein expression and purification.

Dr. Ross has been featured in various peer reviewed publications including “Blood and the Biology of Blood.” and “Marrow Transplantation,” in which he discussed the use of various cell types to suppress immunological diseases.

Dr. Ross heads Kimera Labs and is a board member of the federal nonprofit research organization the Kimera Society. Dr Ross is an expert in stem cell culture and  has developed and patented proprietary methods of stem cell manipulation and licensing using growth factors and nucleic acids.

Joseph Purita, M.D.

Buenos Aires Stem Cell Symposium

Joseph Purita, M.D.
Global Stem Cells Group Advisory Board member

Joseph Purita, M.D., is a world-renowned orthopedic surgeon and stem cell pioneer, using cutting edge technology in regenerative medicine in conjunction with stem cell platelet rich plasma (PRP) therapy to treat orthopedic injuries and relieve pain. He is also a pioneer in the use of the laser in orthopedic surgery.

Named a U.S. News and World Report Top Doctor in 2012, Dr. Purita, a renown orthopedic and arthroscopic surgeon, heads Global Stem Cells Group’s Scientific Advisory Board. A pioneer in the use of stem cell and PRP therapy for orthopedic conditions, Dr. Purita has practiced with the Boca Raton Orthopaedic Group in Boca Raton, Florida since 1981. In 2012, Purita gained international attention when he treated New York Yankees pitcher Bartolo Colon’s ligament damage with stem cells, restoring the athlete’s injured shoulder and career. Purita has since treated an array of professional athletes with career-threatening injuries.

Dr. Purita is the director of the Institute of Regenerative and Molecular Orthopedics in Boca Raton, Florida, specializing in the use of stem cells and PRP injections for use in sports medicine and other musculoskeletal conditions. The Institute has treated some of the most prominent professional athletes from all major sports in both the U.S.. and abroad.

He is an instructor and proctor of surgeons in the use of lasers in arthroscopic and orthopedic surgery at a variety of area hospitals,

Dr. Purita is a Fellow, American Academy of Orthopedic Surgeons; Fellow, American College of Surgeons; member, American Medical Association; member, Southern Medical Association; member, Palm Beach Medical Society; member, Broward County Medical Society; member, Palm Beach Orthopedic Society, and member, Florida Medical Association. His certifications include the American Board of Orthopedic Surgery; American College of Orthopaedic Surgery; American Board of Pain Management, and the American Board of Regenerative Medicine.

He is Is Board Certified By The Following Organizations:
•  American Board of Orthopedic Surgery
•  American College of Orthopaedic Surgery
•  American Board of Pain Management

Dr. Purita is a popular speaker at regenerative and orthopedic conferences worldwide.

 

 

 

 

 

stem cell training course in Barcelona

Global Stem Cells Group and its subsidiary Stem Cell Training, Inc., have announced plans to hold a stem cell training course in Barcelona, Spain, Nov. 11 – 12, 2016. Orthopedic and cosmetic surgeon J. Victor Garcia Gimenez, M.D. will conduct the course for qualified physicians and medical professionals.

stem cell training course in Barcelona

J. Victor Garcia Gimenez, M.D.

MIAMI, Aug. 10, 2016–Global Stem Cells Group and its subsidiary Stem Cell Training, Inc. will host a stem cell training course in Barcelona, Spain, Nov. 11 – 12, 2016. Victor Garcia Gimenez, M.D. will conduct the two-day, intensive, hands-on “Adipose-derived Harvesting, Isolation and Re-integration Training Course” for physicians and qualified medical professionals.

Garcia Gimenez, a member of the Global Stem Cells Group Advisory Board, first conducted the course for GSCG in 2014. The

course is part of the Miami-based biotech company’s growth in the European market.

The training course was developed for physicians and high-level practitioners to learn clinical protocols and state-of-the-art techniques for isolating and re-integrating adipose- and bone marrow-derived stem cells. Stem cells are harvested from the patient’s own body and redistributed to areas of the body receiving treatment. Patients experience an effective, non-invasive procedure, and a faster recovery period with little to no downtime.

Garcia Gimenez is a specialist in orthopedic and cosmetic surgery, president of Therapeutic Confrontations (CONFTERA), and practices cosmetic and anti-aging medicine, as well as aesthetic therapies in Barcelona. He is the president of the Spanish Society of Medicine and Cosmetic Surgery; co-director of the UAB-SEMCC; Chairman for Spain of the International Academy of Cosmetic Surgery, in addition to other medical and professional boards.

The stem cell training course will be offered through Global Stem Cells Group affiliate Stem Cell Training, Inc.

To learn more, visit the Global Stem Cells Group website, or the Stem Cell Training website, email bnovas(at)regenestem(dot)com, or call +1 305 560 5337.

About Global Stem Cell Group:stem cell training course in Barcelona

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

About Stem Cell Training, Inc.:

stem cell training course in BarcelonaStem Cell Training, Inc. is a multi-disciplinary company offering coursework and training in 35 cities worldwide. The coursework offered focuses on minimally invasive techniques for harvesting stem cells from adipose tissue, bone marrow and platelet-rich plasma. By equipping physicians with these techniques, the goal is to enable them to return to their practices, better able to apply these techniques in patient treatment.

To view this press release live online, click here.

###